Additional file 1 of The Alzheimer’s disease drug development landscape

Sasja Heetveld (Contributor)
P. Scheltens (Contributor)
Prisca S. Leferink (Contributor)
Jeffrey Cummings (Contributor)
L. Vermunt (Contributor)
Pieter van Bokhoven (Contributor)
Everard G. B. Vijverberg (Contributor)
Arno de Wilde (Contributor)

Vrije Universiteit Amsterdam

Dataset / Software

Description

Additional file 1 : Table S1. Number of drugs in preclinical (pre) and clinical (clin) development for AD, stratified by target class and treatment modality.

Date made available	1 Jan 2021
Publisher	figshare Academic Research System

DOI
10.6084/m9.figshare.16994107.v1

Access Dataset

https://springernature.figshare.com/articles/dataset/Additional_file_1_of_The_Alzheimer_s_disease_drug_development_landscape/16994107/1

Cite this

DataSetCite

Heetveld, S. (Contributor), Scheltens, P. (Contributor), Leferink, P. S. (Contributor), Cummings, J. (Contributor), Vermunt, L. (Contributor), van Bokhoven, P. (Contributor), Vijverberg, E. G. B. (Contributor), de Wilde, A. (Contributor) (1 Jan 2021). Additional file 1 of The Alzheimer’s disease drug development landscape. figshare Academic Research System. 10.6084/m9.figshare.16994107.v1

Additional file 1 of The Alzheimer’s disease drug development landscape

Description

DOI

Access Dataset

Cite this